CrownCast

What if the next breakthrough in cancer treatment isn't a pill or infusion, but a precisely targeted radioactive payload that hunts down tumor cells like a guided missile? In this Smart Biotech Scientist Podcast episode, Dr. David Brühlmann speaks with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, about the radiopharmaceutical revolution transforming oncology. From theranostic approaches to advanced preclinical modeling, Miller shares insights on how this emerging therapeutic class is reshaping cancer treatment strategies.

When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely.

In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi Suryani Chen, Director of Business Development at Crown Bioscience, to explore where DMPK and toxicology fit into the drug discovery picture and how getting them right can save programs from costly detours.

Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Development and Bryan Miller, Director of Scientific and Technical Operations about leveraging the UK’s vibrant ecosystem of cutting-edge technologies, strong collaborations, and a commitment to high ethical standards.

As cancer research progresses rapidly, obtaining high-quality biospecimens has grown increasingly important for making significant breakthroughs.

In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sadaf Malik, Senior Director, Head US Sales (Biobank and Biomarker) about how superior biospecimens can drive advancements in oncology by means of innovative biobanking.

As the landscape of drug discovery evolves, breakthrough technologies like organoids are gaining traction for their potential to revolutionize how new treatments are developed. In this episode of CrownCast, Jonny McMichael, Vice President at Crown Bioscience, and Leo Price, a member of Crown Bioscience’s Scientific Advisory Board, shed light on organoids' growing role in drug development. With insights into their application, this commentary delves into a technology that offers a significant leap toward personalized medicine, ushering in a new era for the healthcare industry.